-
1.发明公开公开(公告)号：US20240041758A1
公开(公告)日：2024-02-08
申请号：US18227463
申请日：2023-07-28
Applicant: Ocular Therapeutix, Inc.
Inventor： Charles D. Blizzard , Rami El-Hayek , Michael Goldstein , Peter Jarrett , Andrew Vanslette
CPC classification number: A61K9/0051 , A61K38/13 , A61K47/10 , A61K47/22 , A61P27/02
Abstract: Provided herein are sustained release biodegradable intracanalicular insert comprising a hydrogel and cyclosporine, methods of treating or preventing an ocular disease in a subject in need thereof by administering such inserts as well as methods of manufacturing such inserts.
-
2.发明授权公开(公告)号：US11779536B2
公开(公告)日：2023-10-10
申请号：US17681238
申请日：2022-02-25
Applicant: Ocular Therapeutix, Inc.
Inventor： Charles D. Blizzard , Rami El-Hayek , Michael Goldstein , Peter Jarrett , Andrew Vanslette
CPC classification number: A61K9/0051 , A61K38/13 , A61K47/10 , A61K47/22 , A61P27/02
Abstract: Provided herein are sustained release biodegradable intracanalicular insert comprising a hydrogel and cyclosporine, methods of treating or preventing an ocular disease in a subject in need thereof by administering such inserts as well as methods of manufacturing such inserts.
-
公开(公告)号：US11622935B2
公开(公告)日：2023-04-11
申请号：US17673265
申请日：2022-02-16
Applicant: OCULAR THERAPEUTIX, INC.
Inventor： Charles D. Blizzard , Ankita Desai , Arthur Driscoll , Michael Goldstein
IPC: A61K9/00 , A61K9/14 , A61K31/5575 , C08L67/04 , A61K47/69 , A61P27/06 , A61K31/216 , A61K47/10
Abstract: The present invention relates to the treatment of ocular diseases in a human subject In particular, the invention relates to an intracameral administration of a sustained release biodegradable intracameral implant.
-
公开(公告)号：US20220183969A1
公开(公告)日：2022-06-16
申请号：US17549307
申请日：2021-12-13
Applicant: Ocular Therapeutix, Inc.
Inventor： Charles D. Blizzard , Ankita Desai , Michael Goldstein
IPC: A61K9/00 , A61K31/573
Abstract: In certain embodiments, the invention relates to a sustained release biodegradable intracanalicular insert containing a glucocorticoid dispersed in a hydrogel for the treatment of dry eye disease.
-
公开(公告)号：US20210308043A1
公开(公告)日：2021-10-07
申请号：US17210696
申请日：2021-03-24
Applicant: Ocular Therapeutix, Inc.
Inventor： Charles D. Blizzard , Arthur Driscoll , Rami El-Hayek , Michael Goldstein , Joseph Iacona , Peter Jarrett , Timothy S. Jarrett , Erica Kahn , Zachary Lattrell
IPC: A61K9/00 , A61K9/06 , A61K31/4439 , A61K47/34
Abstract: The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.
-
Patent Agency Ranking
公开(公告)号：US20200337990A1
公开(公告)日：2020-10-29
申请号：US16857464
申请日：2020-04-24
Applicant: Ocular Therapeutix, Inc.
Inventor： Michael Goldstein , Arthur Driscoll , Charles D. Blizzard , Ankita Desai
IPC: A61K9/00 , A61K31/215 , A61P27/06 , A61P27/02
Abstract: Provided herein are sustained release biodegradable ocular hydrogel implants which are useful for lowering ocular pressure and for treating related conditions.
-
7.发明授权公开(公告)号：US12161753B2
公开(公告)日：2024-12-10
申请号：US18020544
申请日：2021-09-23
Applicant: OCULAR THERAPEUTIX, INC.
Inventor： Charles D. Blizzard , Rami El-Hayek , Michael Goldstein , Peter Jarrett , Andrew Vanslette
Abstract: Provided herein are sustained release biodegradable intracanalicular inserts comprising a hydrogel and an active agent, methods of treating or preventing an ocular disease in a subject in need thereof by administering such inserts as well as methods of manufacturing such inserts.
-
8.发明授权公开(公告)号：US12109302B2
公开(公告)日：2024-10-08
申请号：US18227463
申请日：2023-07-28
Applicant: Ocular Therapeutix, Inc.
Inventor： Charles D. Blizzard , Rami El-Hayek , Michael Goldstein , Peter Jarrett , Andrew Vanslette
CPC classification number: A61K9/0051 , A61K38/13 , A61K47/10 , A61K47/22 , A61P27/02
Abstract: Provided herein are sustained release biodegradable intracanalicular insert comprising a hydrogel and cyclosporine, methods of treating or preventing an ocular disease in a subject in need thereof by administering such inserts as well as methods of manufacturing such inserts.
-
公开(公告)号：US20230118774A1
公开(公告)日：2023-04-20
申请号：US17991762
申请日：2022-11-21
Applicant: Ocular Therapeutix, Inc.
Inventor： Charles D. Blizzard , Arthur Driscoll , Rami El-Hayek , Michael Goldstein , Joseph Iacona , Peter Jarrett , Timothy S. Jarrett , Erica Kahn , Zachary Lattrell
IPC: A61K9/00 , A61K9/06 , A61K31/4427 , A61K47/34 , A61P27/02 , A61K31/4439
Abstract: The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.
-
10.发明申请公开(公告)号：US20250120906A1
公开(公告)日：2025-04-17
申请号：US18928908
申请日：2024-10-28
Applicant: OCULAR THERAPEUTIX, INC.
Inventor： Charles D. Blizzard , Rami El-Hayek , Michael Goldstein , Peter Jarrett , Andrew Vanslette
Abstract: Provided herein are sustained release biodegradable intracanalicular inserts comprising a hydrogel and an active agent, methods of treating or preventing an ocular disease in a subject in need thereof by administering such inserts as well as methods of manufacturing such inserts.
-
-
-
-
-
-
-
-
-
Search Results
27
records
(took 0.016 seconds)
